- Home
- TDF vs AVIR Comparison
TDF vs AVIR Comparison
Compare TDF & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TDF | AVIR |
|---|---|---|
| Founded | 1994 | 2012 |
| Country | Singapore | US |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 301.0M | 318.0M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | TDF | AVIR |
|---|---|---|
| Price | $11.64 | $4.74 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 113.7K | ★ 580.2K |
| Earning Date | 01-01-0001 | 04-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $351,367,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.13 | $2.46 |
| 52 Week High | $12.20 | $4.70 |
Technical Indicators
Market Signals| Indicator | TDF | AVIR |
|---|---|---|
| Relative Strength Index (RSI) | 47.15 | 71.86 |
| Support Level | $11.48 | $4.04 |
| Resistance Level | $11.77 | $4.50 |
| Average True Range (ATR) | 0.23 | 0.24 |
| MACD | -0.03 | 0.04 |
| Stochastic Oscillator | 21.93 | 93.23 |
Price Performance
Historical ComparisonAbout TDF Templeton Dragon Fund Inc.
Templeton Dragon Fund Inc is a closed-end management investment company. The fund seeks long-term capital appreciation by investing majority of its total assets in equity securities of China companies. It invests in various sectors such as gas & consumable fuels, auto components, banks, beverages, communications equipment, healthcare equipment & supplies, restaurants & leisure, household durables and many others.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).